

Ministry of Health

OHIP, Pharmaceuticals and Devices Division

Drug Submission Status

Report for June 2022

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a OPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Teriflunomide	Aubagio	TERIFLUNOMIDE	14 mg	tablet	02500639
Marcan Pharmaceuticals Inc.	Mar-Teriflunomide	Aubagio	TERIFLUNOMIDE	14 mg	tablet	02500469
Accord Healthcare Inc	Ach-Teriflunomide	Aubagio	TERIFLUNOMIDE	14 mg	tablet	02502933
Mantra Pharma Inc	M-Teriflunomide	Aubagio	TERIFLUNOMIDE	14 mg	tablet	02523833
Jamp Pharma Corporation	Jamp Teriflunomide	Aubagio	TERIFLUNOMIDE	14 mg	tablet	02504170
Sandoz Canada Inc.	Sandoz Teriflunomide	Aubagio	TERIFLUNOMIDE	14 mg	tablet	02505843
Teva Canada Limited	TEVA-Teriflunomide	Aubagio	TERIFLUNOMIDE	14 mg	tablet	02501090

Natco Pharma (Canada) Inc.	NAT-Teriflunomide	Aubagio	TERIFLUNOMIDE	14 mg	tablet	02500310
Sanis Health Inc.	Cinacalcet	Sensipar	CINACALCET	30mg	tablet	02524880
Jamp Pharma Corporation	Jamp Cetirizine	Reactine	CETIRIZINE HYDROCHLORIDE	10 mg	tablet	02517566
Pharmascience Inc.	Pms-Teriflunomide	Aubagio	TERIFLUNOMIDE	14mg	tablet	02500434